ArticleBlood cancer journal2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.Leukemia · 2026Article
- Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations.Journal of clinical medicine · 2026Review
- [Impact of recipient age on outcomes of allogeneic hematopoietic stem cell transplantation: an analysis from the Chinese Bone Marrow Transplant Registry Group (CBMTRG)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Machine learning-guided risk stratification in elderly AML based on genomic, immunophenotypic and therapeutic profiles.BMC geriatrics · 2026Article
- Review
- Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems.Journal of translational medicine · 2026Review
- Consolidation cycles, measurable residual disease, and DNMT3A/ASXL1 mutations independently predict relapse-free survival in older adults with acute myeloid leukemia.Frontiers in oncology · 2026Article
- Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy.Current oncology reports · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Fieke W HoffDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-7128-1255
Ying HuangDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Rina Li WelkieDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Ronan T SwordsDivision of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Elie TraerDivision of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Eytan M SteinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tara L LinDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.ORCID http://orcid.org/0000-0002-0242-6449
Prapti A PatelServier Pharmaceuticals, LLC, Boston, MA, USA.
Robert H CollinsDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Maria R BaerDepartment of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Vu H DuongDepartment of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
William G BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Martha L ArellanoDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Wendy StockDepartment of Medicine, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-8349-9200
Olatoyosi OdenikeDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Robert L RednerDepartment of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Tibor KovacsovicsDivision of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT, USA.
Michael W DeiningerDepartment of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0002-2987-1331
Joshua F ZeidnerDivision of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-9014-1514
Rebecca L OlinDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5060-0384
Catherine C SmithDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0160-7026
James M ForanDepartment of Internal, Medicine Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0003-1673-1708
Gary J SchillerDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7508-3467
Emily K CurranDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Kristin L KoenigDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Nyla A HeeremaDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Timothy ChenDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Molly MartyczDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Mona StefanosDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Sonja G MarcusLeukemia and Lymphoma Society, Rye Brook, NY, USA.
Leonard RosenbergLeukemia and Lymphoma Society, Rye Brook, NY, USA.
Brian J DrukerDivision of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-8331-8206
Ross L LevineDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7884-1905
Amy BurdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Ashley O YocumLeukemia and Lymphoma Society, Rye Brook, NY, USA.
Uma M BorateDepartment of Medicine, The Ohio State University, Columbus, OH, USA.
Alice S MimsDepartment of Medicine, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-8971-2199
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Yazan F MadanatDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. yazan.madanat@utsouthwestern.edu.ORCID http://orcid.org/0000-0001-9573-2690
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2017 to 2026
$13.9MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS U54 CA224019
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.